メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
設備
プロジェクト
研究成果
データセット
受賞
活動
授業
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
安藤 孝将
講師, 博士（医学） 富山大学 2010年3月
内科学（第三）講座
h-index
2071
被引用数
23
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2003
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(3)
研究成果
(104)
データセット
(28)
授業
(12)
類似のプロファイル
(6)
フィンガープリント
Takayuki Andoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Advanced Gastric Cancer
67%
Gastric Cancer
53%
Helicobacter Pylori (H. pylori)
45%
Chemotherapy
45%
Gastric mucosa
36%
Methylation Status
35%
Methylation
35%
Cisplatin
33%
DNA Methylation (DNAm)
32%
Gastrointestinal Stromal Tumor
30%
Epigenetic Modification
28%
Docetaxel
25%
Fluoropyrimidine
25%
Irinotecan
24%
Tumor
23%
5-fluorouracil (5-FU)
23%
Median Progression-free Survival
21%
Aging
21%
Helicobacter Pylori Infection
19%
Nivolumab
18%
Trifluridine-tipiracil
18%
Metastatic Colorectal Cancer (mCRC)
18%
Shakuyakukanzoto
16%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
16%
Gastric Carcinoma
16%
Ramucirumab
16%
Multicenter Retrospective Study
15%
Epigenetic Field Defect
15%
Monotherapy
15%
Endoscopic Submucosal Dissection
15%
Median Overall Survival
15%
Gastrointestinal Cancer
14%
Neutropenia
14%
Gastric Cancer Patients
14%
Japan
13%
Phase II Study
13%
Second-line Chemotherapy
13%
Healthy Volunteers
13%
Neurogenesis
13%
Genetic Modification
13%
Hippocampus
13%
Phase II Trial
13%
Epigenetics
13%
S-1 Plus Cisplatin
12%
Preventive Effect
12%
Metastatic Gastric Cancer
12%
Overall Survival
12%
Mitomycin C
12%
Radiofrequency Ablation
12%
Endoscopic Retrograde Cholangiopancreatography
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Chemotherapy
68%
Malignant Neoplasm
27%
Progression Free Survival
27%
Cisplatin
26%
Adverse Event
25%
Overall Survival
25%
Fluoropyrimidine
25%
Retrospective Study
23%
Irinotecan
22%
Helicobacter Pylori
21%
Docetaxel
18%
Gastric Mucosa
18%
Fluorouracil
18%
Monotherapy
16%
Ramucirumab
16%
Diarrhea
15%
Metastatic Colorectal Cancer
15%
Normal Human
14%
Neoplasm
14%
Nivolumab
13%
Constipation
13%
Clinical Trial
13%
Oxaliplatin
12%
Paclitaxel
12%
Mitomycin
12%
microRNA
12%
Gastrointestinal Stromal Tumor
12%
Trifluridine
12%
Tipiracil
12%
Neuroendocrine Carcinoma
12%
Imatinib
12%
Second-Line Chemotherapy
11%
Helicobacter Infection
11%
First-Line Chemotherapy
10%
Combination Therapy
10%
Digestive System Cancer
9%
Disease
9%
Neurotoxicity
9%
Folinic Acid
8%
Ascites
8%
Infection
8%
Bevacizumab
7%
Immune Checkpoint Inhibitor
7%
Acute Pancreatitis
7%
Placebo
7%
Inflammatory Bowel Disease
7%
Liver Metastasis
7%
Amrubicin
7%
Pancreatitis
7%
Medicine and Dentistry
Abdominal Cancer
71%
Chemotherapy
45%
Neoplasm
28%
Arm
21%
Malignant Neoplasm
21%
Methylation
18%
Nivolumab
18%
Trifluridine
18%
Tipiracil
18%
Helicobacter Pylori
17%
Endoscopic Ultrasound Guided Fine Needle Biopsy
17%
Progression Free Survival
15%
Cisplatin
15%
Endoscopic Submucosal Dissection
15%
Overall Survival
14%
Radiofrequency Ablation
13%
Endoscopic Ultrasound
12%
Retrospective Study
12%
Fine-Needle Aspiration
12%
Gastrointestinal Stromal Tumor
12%
Endoscopic Retrograde Cholangiopancreatography
12%
DNA Mismatch Repair
12%
Thyroid Cancer
12%
Colorectal Carcinoma
12%
Pancreas Cancer
11%
Clinical Trial
11%
Stomach Mucosa
10%
Neuroendocrine Tumor
10%
Biopsy Technique
10%
Microsatellite Instability
9%
Ramucirumab
9%
Quality of Life
9%
Gene Mutation
9%
Constipation
9%
Esophageal Squamous Cell Carcinoma
9%
Fluorouracil
8%
Docetaxel
8%
Endoscopy
8%
Ascites
8%
Ulcer
8%
DNA Methylation
8%
Diagnosis
8%
First-Line Chemotherapy
8%
Helicobacter Infection
7%
Duodenum
7%
Stenting
7%
Metastatic Carcinoma
7%
Promoter Region
7%
Neutropenia
7%
Adverse Event
7%
